An In Vitro Approach for Investigating the Safety of Lipotransfer after Breast-Conserving Therapy.
ADSC
MCF-10A
adipose-derived stem cells
epithelial-mesenchymal transition
fibroblasts
irradiation
mammary epithelial cells
mesenchymal markers
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
05 Aug 2022
05 Aug 2022
Historique:
received:
14
06
2022
revised:
19
07
2022
accepted:
30
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
The application of lipotransfer after breast-conserving therapy (BCT) and irradiation in breast cancer patients is an already widespread procedure for reconstructing volume deficits of the diseased breast. Nevertheless, the safety of lipotransfer has still not been clarified yet due to contradictory data. The goal of this in vitro study was to further elucidate the potential effects of lipotransfer on the irradiated remaining breast tissue. The mammary epithelial cell line MCF-10A was co-cultured with the fibroblast cell line MRC-5 and irradiated with 2 and 5 Gy. Afterwards, cells were treated with conditioned medium (CM) from adipose-derived stem cells (ADSC), and the effects on the cellular functions of MCF-10A cells and on gene expression at the mRNA level in MCF-10A and MRC-5 cells were analyzed. Treatment with ADSC CM stimulated transmigration and invasion and decreased the surviving fraction of MCF-10A cells. Further, the expression of cytokines, extracellular, and mesenchymal markers was enhanced in mammary epithelial cells. Only an effect of ADSC CM on irradiated fibroblasts could be observed. The present data suggest epithelial-mesenchymal transition-like changes in the epithelial mammary breast cell line. Thus, the benefits of lipotransfer after BCT should be critically weighed against its possible risks for the affected patients.
Identifiants
pubmed: 36013233
pii: jpm12081284
doi: 10.3390/jpm12081284
pmc: PMC9409821
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : ELAN FAU
ID : 18-12-19-1
Références
Dev Biol. 2010 Oct 1;346(1):11-24
pubmed: 20624380
J Plast Reconstr Aesthet Surg. 2016 Apr;69(4):475-81
pubmed: 26876108
J Cell Biol. 2000 Feb 21;148(4):779-90
pubmed: 10684258
Front Mol Biosci. 2019 Aug 13;6:70
pubmed: 31475157
Aesthet Surg J. 2016 Mar;36(3):358-63
pubmed: 26499941
J Cell Biol. 1999 Nov 1;147(3):631-44
pubmed: 10545506
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Gland Surg. 2019 Oct;8(5):569-580
pubmed: 31741888
Cancers (Basel). 2020 Jun 26;12(6):
pubmed: 32604738
N Engl J Med. 2002 Oct 17;347(16):1227-32
pubmed: 12393819
Mol Carcinog. 2020 Jul;59(7):754-765
pubmed: 32363633
Sci Rep. 2019 Jul 24;9(1):10722
pubmed: 31341222
BMC Cancer. 2010 Aug 06;10:411
pubmed: 20691079
Plast Reconstr Surg. 2007 Apr 15;119(5):1409-1422
pubmed: 17415234
Front Oncol. 2020 Feb 18;10:157
pubmed: 32133294
BMC Cancer. 2011 Apr 12;11:130
pubmed: 21486440
Stem Cells Int. 2015;2015:120949
pubmed: 26000019
Plast Reconstr Surg. 2017 Sep;140(3):382e-392e
pubmed: 28841600
Cancer Metastasis Rev. 2016 Dec;35(4):655-667
pubmed: 27914000
Open Med (Wars). 2022 Feb 17;17(1):329-340
pubmed: 35274048
Cancer Res. 2011 Jul 1;71(13):4707-19
pubmed: 21555371
Neoplasma. 2011;58(5):361-70
pubmed: 21744988
Cancer Res. 2003 May 15;63(10):2658-64
pubmed: 12750294
Cancer Res. 2008 Feb 15;68(4):989-97
pubmed: 18281472
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Future Oncol. 2017 Jul;13(17):1537-1550
pubmed: 28685611
J Biomed Mater Res A. 2022 Sep;110(9):1551-1563
pubmed: 35484827
Development. 2019 Dec 2;146(23):
pubmed: 31699800
Front Oncol. 2022 Jun 22;12:820968
pubmed: 35814391
BMC Cancer. 2022 Apr 11;22(1):391
pubmed: 35410265
Stem Cells Dev. 2013 Dec 1;22(23):3114-27
pubmed: 23895436
Ann Surg Oncol. 2016 Mar;23(3):776-81
pubmed: 26467459
Stem Cells. 2017 Sep;35(9):2060-2070
pubmed: 28514506
J Pers Med. 2022 Feb 08;12(2):
pubmed: 35207725
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Semin Cancer Biol. 2022 Aug;83:556-569
pubmed: 33035656
Cell Oncol (Dordr). 2020 Feb;43(1):1-18
pubmed: 31900901
Cancer Res. 2012 Mar 1;72(5):1290-300
pubmed: 22253230
Br J Cancer. 2003 Nov 17;89(10):1817-21
pubmed: 14612884
Discov Med. 2018 May;25(139):211-223
pubmed: 29906404
Plast Reconstr Surg. 2017 May;139(5):1223-1232
pubmed: 28092338
Cell Oncol (Dordr). 2018 Aug;41(4):369-378
pubmed: 29497991
Tissue Eng Part C Methods. 2008 Sep;14(3):261-71
pubmed: 18694322
Sci Rep. 2016 Feb 01;6:20208
pubmed: 26831400
FEBS J. 2011 Jan;278(1):16-27
pubmed: 21087457
Curr Opin Cell Biol. 2005 Oct;17(5):548-58
pubmed: 16098727
Plast Reconstr Surg. 2004 Nov;114(6):1442-9
pubmed: 15509931
Aesthetic Plast Surg. 2018 Oct;42(5):1195-1201
pubmed: 29948094
J Cancer. 2017 Feb 25;8(4):674-682
pubmed: 28367247
J Plast Reconstr Aesthet Surg. 2014 Apr;67(4):437-48
pubmed: 24394754
JAMA Surg. 2019 Jan 1;154(1):56-63
pubmed: 30304330
Ann Oncol. 2013 Jun;24(6):1479-84
pubmed: 23393126
Lancet. 2013 Sep 28;382(9898):1113-20
pubmed: 24075051
Cancer Lett. 2012 Dec 28;325(2):175-88
pubmed: 22776560
Cell Biol Int. 2014 Feb;38(2):254-65
pubmed: 24155046
Breast Cancer Res. 2004;6(3):R215-31
pubmed: 15084245
Cancer Res. 2007 Sep 15;67(18):8662-70
pubmed: 17875706
Breast Cancer Res. 2003;5(4):208-15
pubmed: 12817994
Aesthetic Plast Surg. 2008 Jan;32(1):48-55; discussion 56-7
pubmed: 17763894
Ann Plast Surg. 2012 May;68(5):435-7
pubmed: 22531396
Cells. 2021 Aug 13;10(8):
pubmed: 34440843
Int J Breast Cancer. 2014;2014:839094
pubmed: 24800085
Cell Commun Signal. 2019 May 17;17(1):47
pubmed: 31101063
Front Surg. 2022 Feb 15;9:729181
pubmed: 35242802
Biochem Biophys Res Commun. 2010 Sep 3;399(4):659-64
pubmed: 20691661
Cell Mol Biol Lett. 2018 Sep 17;23:44
pubmed: 30237810